Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

Jain, P; Zhang, SJ; Kanagal-Shamanna, R; Ok, CY; Nomie, K; Gonzalez, GN; Gonzalez-Pagan, O; Hill, HA; Lee, HJ; Fayad, L; Westin, J; Nastoupil, L; Hagemeister, F; Chen, W; Oriabure, O; Badillo, M; Jiang, CY; Yao, YX; Li, SY; Tang, GL; Yin, CC; Patel, KP; Medeiros, LJ; Nair, R; Ahmed, S; Iyer, SP; Thirumurthi, S; Champlin, R; Xu, GF; Pan, TS; Santos, D; Wang, RP; Han, GC; Zhang, JH; Song, XZ; Neelapu, S; Romaguera, J; Futreal, A; Flowers, C; Fowler, N; Wang, LH; Wang, ML

Wang, ML (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, 1515 Holcombe Blvd, Houston, TX 77030 USA.

BLOOD ADVANCES, 2020; 4 (6): 1038

Abstract

Blastoid and pleomorphic mantle cell lymphomas (MCLs) are variants of aggressive histology MCL (AH-MCL). AH-MCL can arise de novo (AH-DN) or transform......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索